Ocvirk J - Search Results

1

Metabolic impact of anti-angiogenic agents on U87 glioma cells.

Mesti T, Savarin P, Triba MN, Le Moyec L, Ocvirk J, Banissi C, Carpentier AF. Mesti T, et al. Among authors: ocvirk j. PLoS One. 2014 Jun 12;9(6):e99198. doi: 10.1371/journal.pone.0099198. eCollection 2014. PLoS One. 2014. PMID: 24922514 Free PMC article.

2

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience.

Mesti T, Moltara ME, Boc M, Rebersek M, Ocvirk J. Mesti T, et al. Among authors: ocvirk j. Radiol Oncol. 2015 Mar 3;49(1):80-5. doi: 10.2478/raon-2014-0021. eCollection 2015 Mar. Radiol Oncol. 2015. PMID: 25810706 Free PMC article.

3

The cost of systemic therapy for metastatic colorectal carcinoma in Slovenia: discrepancy analysis between cost and reimbursement.

Mesti T, Boshkoska BM, Kos M, Tekavčič M, Ocvirk J. Mesti T, et al. Among authors: ocvirk j. Radiol Oncol. 2015 Mar 25;49(2):200-8. doi: 10.2478/raon-2014-0046. eCollection 2015 Jun. Radiol Oncol. 2015. PMID: 26029033 Free PMC article.

4

Malignant gliomas: old and new systemic treatment approaches.

Mesti T, Ocvirk J. Mesti T, et al. Among authors: ocvirk j. Radiol Oncol. 2016 Apr 23;50(2):129-38. doi: 10.1515/raon-2015-0003. eCollection 2016 Jun 1. Radiol Oncol. 2016. PMID: 27247544 Free PMC article. Review.

5

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience.

Ocvirk J, Moltara ME, Mesti T, Boc M, Rebersek M, Volk N, Benedik J, Hlebanja Z. Ocvirk J, et al. Radiol Oncol. 2016 Apr 23;50(2):226-31. doi: 10.1515/raon-2015-0030. eCollection 2016 Jun 1. Radiol Oncol. 2016. PMID: 27247556 Free PMC article.

6

Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells.

Mesti T, Bouchemal N, Banissi C, Triba MN, Marbeuf-Gueye C, Cemazar M, Moyec LL, Carpentier AF, Savarin P, Ocvirk J. Mesti T, et al. Among authors: ocvirk j. Radiol Oncol. 2018 Nov 26;52(4):392-398. doi: 10.2478/raon-2018-0046. Radiol Oncol. 2018. PMID: 30511933 Free PMC article.

7

Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients.

Rebersek M, Mesti T, Boc M, Ocvirk J. Rebersek M, et al. Among authors: ocvirk j. Radiol Oncol. 2019 Mar 3;53(1):85-95. doi: 10.2478/raon-2019-0013. Radiol Oncol. 2019. PMID: 30840593 Free PMC article.

8

Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience.

Hribernik N, Boc M, Ocvirk J, Knez-Arbeiter J, Mesti T, Ignjatovic M, Rebersek M. Hribernik N, et al. Among authors: ocvirk j. Radiol Oncol. 2020 Jan 19;54(1):119-127. doi: 10.2478/raon-2020-0003. Radiol Oncol. 2020. PMID: 31955148 Free PMC article.

9

Adverse events during immunotherapy in Slovenian patients with metastatic melanoma reveal a positive correlation with better treatment outcomes.

Mesti T, Ceplak Mencin V, Mileva Boshkoska B, Ocvirk J. Mesti T, et al. Among authors: ocvirk j. Radiol Oncol. 2021 May 4;55(3):354-361. doi: 10.2478/raon-2021-0019. Radiol Oncol. 2021. PMID: 33939899 Free PMC article.

10

Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia.

Mesti T, Sever M, Ocvirk J. Mesti T, et al. Among authors: ocvirk j. Dermatology. 2023;239(1):158-164. doi: 10.1159/000525612. Epub 2022 Jul 27. Dermatology. 2023. PMID: 35896082 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

45 results

Search Page